Infectious Disease · Greenbelt, MD
NPI
1902819196
Since 2006
Specialty
Infectious Disease
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
7721 Belle Point Dr
Greenbelt, MD, 20770
Phone (301) 345-1272
Groups this clinician bills Medicare through
Medicare paid, 2024
$252K
3,311 services
Medicare patients, 2024
612
Average age 75
Drug cost, 2024
$2.2M
767 prescriptions
Company payments, 2025
$88.23
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amirali Amjadi was code 99232 (hospital e&m - subsequent), 2,292 times for 487 patients. In total Amirali Amjadi billed 3,311 services in 11 codes, and Medicare paid $252K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,292 | 487 | $59.71 | $137K |
| 99223 Hospital E&M - Initial | Facility | 527 | 463 | $128.65 | $68K |
| 99233 Hospital E&M - Subsequent | Facility | 244 | 103 | $91.50 | $22K |
| 99214 Office E&M - Established | Office | 199 | 78 | $90.21 | $18K |
| 99205 Office E&M - New | Office | 18 | 18 | $172.02 | $3,096 |
| 99495 Chronic, Principal, and Transitional Care Management | Office | 12 | 12 | $166.33 | $1,996 |
By year: 2022 $230K for 2,720 services; 2023 $292K for 3,447 services; 2024 $252K for 3,311 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amirali Amjadi prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 216 prescriptions and refills. In total Amirali Amjadi wrote 767 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 216 | 248 | 28 | $995K |
| Prezcobix Darunavir/Cobicistat | 81 | 81 | Under 11 | $193K |
| Juluca Dolutegravir/Rilpivirine | 77 | 83 | 12 | $308K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 68 | 68 | Under 11 | $244K |
| Tivicay Dolutegravir Sodium | 50 | 50 | Under 11 | $108K |
| Isentress Raltegravir Potassium | 30 | 30 | Under 11 | $60K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 23 | 23 | Under 11 | $99K |
| Meropenem Generic | 22 | 22 | Under 11 | $2,977 |
| Tenofovir Disoproxil Fumarate Generic | 16 | 36 | Under 11 | $9,303 |
| Sodium Chloride 0.9 % Sodium Chloride | 15 | 15 | Under 11 | $55.99 |
| Ceftriaxone Ceftriaxone Sodium | 15 | 15 | Under 11 | $1,666 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 13 | 15 | Under 11 | $184 |
| Descovy Emtricitabine/Tenofov Alafenam | 12 | 12 | Under 11 | $27K |
| Dificid Fidaxomicin | 11 | 11 | Under 11 | $77K |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 11 | 13 | Under 11 | $11K |
Brand drugs: 616 claims; generic drugs: 151 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amirali Amjadi $88.23 ($88.23 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $88.23.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 4 | $88.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.